Abstract 1371P
Background
Malignant pleural effusion (MPE) is a significant complication in patients (pts) with advanced NSCLC, precipitating a pronounced decline in quality of life and severe symptoms, typically attributed to tumor cells disseminate into the pleura, obstruct lymphatic drainage and increase capillary permeability. Talc currently stands as the sole approved medicine for MPE, despite its potential for inducing strong pain and pleurisy.
Methods
Enrolled NSCLC Pts with symptomatic MPE underwent thoracentesis and received intrapleural (IP) infusions of M701. Simultaneously, systemic treatment was administrated as determined by investigators. Primary endpoints included dose limiting toxicities (DLT) and incidence of AEs. Evaluation of MPE efficacy was based on CT-measured pleural fluids volume and the puncture-free survival (PuFS) interval post-M701 treatment. Additional secondary endpoints comprised overall survival (OS) and pharmacokinetics parameters of M701.
Results
As of April 19, 2024, 24 pts were enrolled, with a median age 65 years, 29.2% male, 58.3% harboring EGFR mutation. Median prior lines of treatment were 3. In the dose escalation phase, 11 patients received M701 doses ranging from 25-400 μg on days 1, 4, 7, and 10, while 6 and 7 patients in the dose expansion phase received 4 or 6 doses of M701 every 3 days, respectively. No DLT was reported, with a 16.7% incidence of SAEs, all unrelated to M701. Notably, the only 1 case of ≥grade 3 TRAE was neutropenia. At 4 weeks from enrollment, 61.5% pts in the dose expansion phase had >50% MPE volume decreased (including 2 CR) and successful pleurodesis. The median PuFS of all pts exceeded 129 days, with 14 pts had no re-puncture at the data cutoff. OS data remained immature. Flow cytometry analysis revealed 95% pts had EpCAM+ cells decreased significantly in effusions after the initial 3 M701 infusions.
Conclusions
IP infusion with M701 demonstrates a favorable safety profile and efficacy on preventing the re-accumulation of pleural effusions. And RP2D had been decided (400μg, 4 doses). Data accrual of efficacy and safety parameters within a controlled phase II trial exploring IP infusion of M701 or cisplatin in MPE pts is ongoing.
Clinical trial identification
NCT05543330.
Editorial acknowledgement
Legal entity responsible for the study
Wuhan YZY Biopharma Co., Ltd.
Funding
Wuhan YZY Biopharma Co., Ltd.
Disclosure
P. Zhou: Financial Interests, Personal, Stocks or ownership: Wuhan YZY Biopharma Co., Ltd. S. Huang, M. Pei, L. Huang: Financial Interests, Personal, Full or part-time Employment: Wuhan YZY Biopharma Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
1352P - Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy
Presenter: Marco Russano
Session: Poster session 06
1353P - Efficacy and safety of docetaxel in combination with nintedanib or ramucirumab following immune checkpoint-Inhibitor treatment in patients with non-small cell lung cancer
Presenter: Konstantinos Ferentinos
Session: Poster session 06
1354P - Retrospective audit to determine the effect of antibiotic therapy on immune checkpoint inhibitor efficacy in stage IV NSCLC
Presenter: Deevyashali Parekh
Session: Poster session 06
1356P - Transcriptomic inflammatory profiling of non-small cell lung cancer: Insights from a 7-gene expression analysis
Presenter: Elba Marin
Session: Poster session 06
1357P - Multicenter phase II study of cisplatin and gemcitabine plus necitumumab in patients with unresectable, advanced lung squamous cell carcinoma who have progressed on or after initial treatment with immune checkpoint inhibitors plus platinum-based chemotherapy: WJOG14120L NESSIE study
Presenter: Hiroshige Yoshioka
Session: Poster session 06
1358P - Plinabulin/docetaxel versus docetaxel in survival benefits of 2L/3L EGFR wild-type NSCLC after platinum regimens (DUBLIN-3): A randomized phase III trial
Presenter: Trevor Feinstein
Session: Poster session 06
1359P - Lack of Abscopal effect and radiotherapy-induced lymphocyte depletion in advanced non-small cell lung cancer (NSCLC) patients treated with atezolizumab and radiotherapy
Presenter: Alexander Meisel
Session: Poster session 06
1361P - The Stereotactic Radiosurgery-Brain Prognostic Index (SRS-BPI): A novel prognostic index for lung cancer patients with brain metastases eligible for SRS
Presenter: Andreas Koulouris
Session: Poster session 06